Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry J Henk

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Clinical Lung Cancer|May 25, 2020
A Population-based Study of Immunotherapy-related Toxicities in Lung CancerElizabeth J Cathcart-Rake, Lindsey R Sangaralingham, Henry J Henk, et al.
Sexually Transmitted Diseases|October 1, 2020
Estimating Recommended Gonorrhea and Chlamydia Treatment Rate Using Linked Medical Claims, Prescription, and Laboratory Data in US Private SettingsGuoyu Tao, Kimberly Workowski, Katherine E Bowden, et al.
Pharmacoeconomics|May 26, 2007
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemiaTheodore Darkow, Henry J Henk, Simu K Thomas, et al.
BMJ (Clinical Research Ed.)|August 3, 2018
Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort studyMolly Moore Jeffery, W Michael Hooten, Henry J Henk, et al.
BMC Pulmonary Medicine|August 2, 2023
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatmentMichelle B Herberts, Taylor T Teague, Viengneesee Thao, et al.
Leukemia & Lymphoma|December 7, 2020
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrolleesEric J Chow, David R Doody, Jennifer J Wilkes, et al.
Annals of Emergency Medicine|October 3, 2017
Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term UseMolly Moore Jeffery, W Michael Hooten, Erik P Hess, et al.
JCO Oncology Practice|August 22, 2020
Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic MalignanciesJennifer J Wilkes, Gary H Lyman, David R Doody, et al.
Fertility and Sterility|February 26, 2022
Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivorsBeth Zhou, Brian Kwan, Milli J Desai, et al.
Current Medical Research and Opinion|December 14, 2017
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient settingHenry J Henk, Feng Cao, Kenneth Tuell, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Clinical Lung Cancer|May 25, 2020
A Population-based Study of Immunotherapy-related Toxicities in Lung CancerElizabeth J Cathcart-Rake, Lindsey R Sangaralingham, Henry J Henk, et al.
Sexually Transmitted Diseases|October 1, 2020
Estimating Recommended Gonorrhea and Chlamydia Treatment Rate Using Linked Medical Claims, Prescription, and Laboratory Data in US Private SettingsGuoyu Tao, Kimberly Workowski, Katherine E Bowden, et al.
Pharmacoeconomics|May 26, 2007
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemiaTheodore Darkow, Henry J Henk, Simu K Thomas, et al.
BMJ (Clinical Research Ed.)|August 3, 2018
Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort studyMolly Moore Jeffery, W Michael Hooten, Henry J Henk, et al.
BMC Pulmonary Medicine|August 2, 2023
Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatmentMichelle B Herberts, Taylor T Teague, Viengneesee Thao, et al.
Leukemia & Lymphoma|December 7, 2020
Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrolleesEric J Chow, David R Doody, Jennifer J Wilkes, et al.
Annals of Emergency Medicine|October 3, 2017
Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term UseMolly Moore Jeffery, W Michael Hooten, Erik P Hess, et al.
JCO Oncology Practice|August 22, 2020
Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic MalignanciesJennifer J Wilkes, Gary H Lyman, David R Doody, et al.
Fertility and Sterility|February 26, 2022
Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivorsBeth Zhou, Brian Kwan, Milli J Desai, et al.
Current Medical Research and Opinion|December 14, 2017
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient settingHenry J Henk, Feng Cao, Kenneth Tuell, et al.
Pageof 5